<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>ER/PR negative, HER2-negative (triple-negative) breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">ER/PR negative, HER2-negative (triple-negative) breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">ER/PR negative, HER2-negative (triple-negative) breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carey K Anders, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa A Carey, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H98882311"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Triple-negative breast cancer (TNBC) is a term that has historically been applied to cancers that lack expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC tends to behave more aggressively than other types of breast cancer. Unlike other breast cancer subtypes (ie, ER-positive, HER2-positive subtypes), there are no approved targeted treatments available, although immunotherapy (in combination with chemotherapy) is available for those with advanced TNBC that expresses programmed cell death ligand 1 (PD-L1). For purposes of this review, we consider "triple-negative" to mean cancers that have &lt;1 percent expression of ER and PR as determined by immunohistochemistry (IHC), and that are, for HER2, either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH) negative (not amplified), according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [<a href="#rid1">1-3</a>]. Although the basic principles of diagnosis and management of TNBC are similar to those of breast cancer in general, many aspects, including risk factors, molecular and pathologic characteristics, natural history, and chemotherapy sensitivity, are unique to TNBC and will be reviewed here.</p><p>A more extensive discussion on surgical management, neoadjuvant chemotherapy, adjuvant chemotherapy of non-metastatic breast cancer, and the treatment of metastatic breast cancer is covered separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/737.html" rel="external">"Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H267308777"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>TNBC accounts for approximately 15 percent of breast cancers diagnosed worldwide, which amounts to almost 200,000 cases each year [<a href="#rid4">4</a>]. Compared with hormone receptor-positive breast cancer, TNBC is more commonly diagnosed in women younger than 40 years. In one study, there was a twofold higher attributable risk of TNBC in women under 40 years compared with women over 50 years (odds ratio [OR] 2.13, 95% CI 1.34-3.39) [<a href="#rid5">5</a>]. In addition, TNBC appears to be relatively more common among Black women compared with White women (OR 2.41, 95% CI 1.81-3.21) [<a href="#rid5">5</a>].</p><p>Risk factors associated with the diagnosis of TNBC include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive </strong><strong><em>BRCA</em></strong><strong> mutation status</strong> – Up to 20 percent of patients with TNBC harbor a breast cancer susceptibility gene (<em>BRCA</em>) mutation, particularly in <em>BRCA1</em> [<a href="#rid6">6</a>]. By contrast, less than 6 percent of all breast cancers are associated with a <em>BRCA</em> mutation. Given this finding, any patient with triple-negative disease should be offered a referral to a genetic counselor to discuss <em>BRCA </em>germline testing [<a href="#rid7">7</a>]. Moreover, any patient age 60 years or younger with TNBC should undergo <em>BRCA</em> germline testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race/ethnicity</strong> – Several population-based studies have found that African American women have a higher risk of TNBC compared with White women [<a href="#rid8">8,9</a>]. However, African American women can certainly have ER-positive and/or HER2-positive disease, and testing their tumors for these markers is essential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premenopausal status</strong> – Premenopausal status has been associated with increased incidence of TNBC diagnosis as compared with postmenopausal status [<a href="#rid8">8,10</a>]. As with African American women, premenopausal women can frequently have ER-positive and/or HER2-positive disease, and testing their tumors for these markers is essential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other factors</strong> – Studies have suggested relationships between other factors such as obesity and a young age of first pregnancy with an increased risk of TNBC, while breastfeeding and parity may be associated with lower risks [<a href="#rid5">5,8,11-13</a>]. However, these factors are less well validated and rarely factor into clinical considerations.</p><p></p><p class="headingAnchor" id="H274813343"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>TNBCs present with rapid growth, and are more likely to be diagnosed clinically rather than mammographically than ER-positive cancers [<a href="#rid14">14</a>] or as interval cancers between mammograms [<a href="#rid15">15</a>]. However, intrinsic differences in the density of breast tissue among women diagnosed with TNBC may also explain these differences in presentation. (See  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H98882326"><span class="h1">PATHOLOGIC CHARACTERISTICS</span><span class="headingEndMark"> — </span>TNBC is usually high grade, and the most common histology is infiltrating ductal carcinoma [<a href="#rid16">16</a>], although a rare histologic subtype, medullary carcinoma, is generally triple negative. TNBCs can exhibit geographic necrosis, a pushing border of invasion, and a stromal lymphocytic response  (<a class="graphic graphic_table graphicRef81333" href="/d/graphic/81333.html" rel="external">table 1</a>) [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/783.html" rel="external">"Pathology of breast cancer"</a>.)</p><p>An uncommon subgroup of TNBCs is defined histopathologically as metaplastic. However, this is a diverse group of cancer types ranging from squamous to stromal in nature. These cancers are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/783.html" rel="external">"Pathology of breast cancer", section on 'Metaplastic carcinoma'</a>.)</p><p>By definition, TNBC lacks immunohistochemical (IHC) expression of the ER, PR, and HER2. Cut-offs used for ER, PR, and HER2 to make this diagnosis are discussed below. (See <a class="local">'Diagnosis and staging'</a> below.)</p><p>Since these three biomarkers represent the only known approved targets for breast cancer treatment, considerable effort has been made to better understand other biologic forces driving TNBC.</p><p class="headingAnchor" id="H493962740"><span class="h2">Molecular classification of TNBC</span><span class="headingEndMark"> — </span>The triple-negative clinical phenotype mostly comprises the basal-like molecular subtype, although triple-negative and basal breast cancers are not synonymous and there is substantial heterogeneity within TNBCs.</p><p>As examples, in one study of utilizing DNA and RNA profiling of TNBCs, four stable subtypes were identified: luminal androgen receptor, mesenchymal, basal-like immunosuppressed, and basal-like immune-activated [<a href="#rid17">17</a>]. In another study, 172 triple-negative tumors based on IHC staining were correlated with gene expression profiles that defined the basal subtype [<a href="#rid18">18</a>]. Only 71 percent of TNBCs were assigned the basal subtype. In a converse analysis (where subtype was identified and correlated with IHC staining) of 160 tumors, 77 percent of basal tumors were triple negative by IHC. Other evidence from copy number variation and mutational analyses has also suggested wide variability and breadth of clonal spectra in TNBC [<a href="#rid19">19</a>].</p><p>Basal breast cancer is characterized by the genomic expression of the "basal cluster," a unique cluster of genes that includes the epidermal growth factor receptor (<em>EGFR</em>, also called <em>HER1</em>), basal cytokeratins 5/6, c-Kit, the proliferation cluster, and low expression of the hormone receptor- and HER2-related genes [<a href="#rid16">16,20-22</a>]. Separate subtypes of TNBC have been characterized by gene expression, including two basal-like subtypes (BL1 and BL2), as well as immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal androgen subtypes [<a href="#rid23">23</a>]. Additional subtypes that have been characterized include claudin-low and interferon-rich subtypes [<a href="#rid24">24,25</a>]. The different subtypes of TNBCs are covered separately. (See  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer"</a>.)</p><p>Gene expression analysis has also revealed that the tumor suppressor gene p53 (<em>TP53</em>) and several DNA repair genes, particularly the breast cancer susceptibility genes (<em>BRCA</em>), are either mutated or aberrantly expressed in TNBC. These molecular features may have implications for chemotherapy sensitivity to platinum and other directly DNA-damaging agents [<a href="#rid26">26,27</a>]. (See <a class="local">'Metastatic disease'</a> below.)</p><p>Taken together, these studies have produced mixed results with varying conclusions among the different investigators. None has reached the level of providing clinical considerations at present.</p><p class="headingAnchor" id="H1340632742"><span class="h1">DIAGNOSIS AND STAGING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – We consider "triple-negative" to mean cancers that have &lt;1 percent expression of ER and PR as determined by immunohistochemistry (IHC), and that are either 0 to 1+ by IHC, or IHC 2+ and fluorescence in situ hybridization (FISH)-negative (not amplified), according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/d/html/747.html" rel="external">"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy"</a> and  <a class="medical medical_review" href="/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'Testing for HER2 expression'</a>.)</p><p></p><p class="bulletIndent1">Receptor testing and the cut-offs used to determine ER, PR, and HER2 statuses were developed to determine the odds of response to endocrine and HER2-directed therapy, respectively. They were not developed to distinguish a distinct biologic subtype of breast cancer, such as the "triple-negative" phenotype. (See  <a class="medical medical_review" href="/d/html/782.html" rel="external">"Prognostic and predictive factors in early, non-metastatic breast cancer", section on 'Receptor status'</a> and  <a class="medical medical_review" href="/d/html/88415.html" rel="external">"Prognostic and predictive factors in metastatic breast cancer", section on 'Tests done on metastatic tissue'</a>.)</p><p></p><p class="bulletIndent1">In support of this definition of ER and PR receptor-negative status, an analysis of cooperative group studies with centrally determined ER, PR, and molecular subtype suggests that this group is molecularly heterogeneous, including both luminal and nonluminal subtypes [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/747.html" rel="external">"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy", section on 'Assays for ER and PR'</a> and  <a class="medical medical_review" href="/d/html/780.html" rel="external">"HER2 and predicting response to therapy in breast cancer", section on 'Testing for HER2 expression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The indications for radiographic staging in breast cancer, as well as appropriate imaging modalities, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Postdiagnosis evaluation'</a> and  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Staging'</a>.)</p><p></p><p class="bulletIndent1">The clinical staging of breast cancer is identical across breast cancer subtypes using the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) Tumor, Node, Metastasis (TNM) breast cancer staging system  (<a class="graphic graphic_table graphicRef110848" href="/d/graphic/110848.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef110851" href="/d/graphic/110851.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef117141" href="/d/graphic/117141.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/744.html" rel="external">"Clinical features, diagnosis, and staging of newly diagnosed breast cancer", section on 'Staging'</a>.)</p><p></p><p class="headingAnchor" id="H3948487481"><span class="h1">GENETICS EVALUATION</span></p><p class="headingAnchor" id="H879742381"><span class="h2">BRCA testing</span><span class="headingEndMark"> — </span>In light of the association of particular breast cancer susceptibility gene 1 (<em>BRCA1</em>) mutations with TNBC, we recommend that women diagnosed at 60 years or younger with a localized TNBC, or those of any age with metastatic TNBC, undergo <em>BRCA</em> mutation testing regardless of family history. (See  <a class="medical medical_review" href="/d/html/753.html" rel="external">"Genetic testing and management of individuals at risk of hereditary breast and ovarian cancer syndromes"</a>.)</p><p>For those with metastatic disease, results of <em>BRCA</em> testing have therapeutic implications. (See <a class="local">'Metastatic disease'</a> below.)</p><p class="headingAnchor" id="H98882362"><span class="h1">NON-METASTATIC DISEASE</span><span class="headingEndMark"> — </span>The neoadjuvant or adjuvant chemotherapy options for patients with TNBC are similar to the approaches used in other breast cancer phenotypes. The principles for the surgical management of and radiation therapy options for breast cancer are also applied in a similar way across breast cancer subtypes. (See  <a class="medical medical_review" href="/d/html/807.html" rel="external">"Breast-conserving therapy"</a> and  <a class="medical medical_review" href="/d/html/760.html" rel="external">"The role of local therapies in metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/739.html" rel="external">"Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/789.html" rel="external">"Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer"</a>.)</p><p class="headingAnchor" id="H4174424936"><span class="h2">Tumors &gt;0.5 cm</span></p><p class="headingAnchor" id="H2816668864"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapy is recommended for women with TNBC &gt;0.5 cm or with node-positive TNBC (regardless of tumor size). These patients have a higher risk of relapse compared with other breast cancer phenotypes and are not candidates for other forms of targeted therapy (ie, HER2-directed treatment or endocrine therapy).</p><p class="headingAnchor" id="H2575613477"><span class="h4">Neoadjuvant versus adjuvant administration</span><span class="headingEndMark"> — </span>Neoadjuvant chemotherapy (NACT) is the preferable approach in patients with locally advanced breast cancer or for those who are not candidates for or unlikely to have a good cosmetic outcome with breast conservation. For patients receiving NACT, pathologic complete response is associated with improvement in disease-free survival (DFS) [<a href="#rid30">30-32</a>]. Additionally, patients with smaller (eg, T1c) TNBCs may be offered neoadjuvant therapy, particularly if they might be candidates for additional treatments in the adjuvant setting if residual disease is identified. The approach to neoadjuvant therapy for patients with breast cancer, including further discussion of appropriate candidates, with special considerations for those with TNBC, is found elsewhere. (See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer"</a> and  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Patient selection'</a> and  <a class="medical medical_review" href="/d/html/122902.html" rel="external">"Choice of neoadjuvant chemotherapy for HER2-negative breast cancer", section on 'Special considerations for triple-negative disease'</a>.)</p><p>The role for additional chemotherapy in the adjuvant setting for women with residual cancer after neoadjuvant chemotherapy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Patients who received neoadjuvant treatment'</a>.)</p><p class="headingAnchor" id="H954904783"><span class="h4">Benefits</span><span class="headingEndMark"> — </span>Stage for stage, there is a larger absolute benefit to adjuvant chemotherapy among patients with TNBC compared with those with hormone-positive disease [<a href="#rid33">33</a>].</p><p>In an analysis of three randomized trials that involved a total of 6644 women with node-positive breast cancer, compared with those with ER-positive breast cancer, patients with ER-negative breast cancer had the following significant outcomes at five years following adjuvant chemotherapy [<a href="#rid33">33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A larger reduction in the risk of recurrence (55 versus 26 percent). This translated into a higher absolute improvement in DFS (23 versus 7 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A larger reduction in the risk of death (55 versus 23 percent). This translated into a higher absolute improvement in overall survival (OS; 17 versus 4 percent).</p><p></p><p>These data emphasize the importance of neo/adjuvant chemotherapy for women with TNBC, who (unlike those with ER-positive or HER2-positive breast cancer) are not eligible for targeted therapies.</p><p class="headingAnchor" id="H1215316192"><span class="h4">Choice of regimen</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimen</strong> – Anthracycline-, alkylator-, and taxane-based chemotherapy regimens remain the standard regimens for TNBC, for example, dose-dense <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> followed by <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (AC-T)  (<a class="graphic graphic_table graphicRef55933" href="/d/graphic/55933.html" rel="external">table 5</a>). Taxanes have significant activity in the treatment of TNBC, and there are no meaningful data regarding regimens lacking alkylator-based therapy [<a href="#rid34">34-36</a>]. As an example of the benefits of a taxane, in the GEICAM 9906 trial of adjuvant <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, and cyclophosphamide (FEC) versus FEC followed by paclitaxel, the addition of paclitaxel was associated with an improvement in DFS at seven years (74 versus 56 percent, respectively) [<a href="#rid36">36</a>]. The ABC trials tested anthracycline/taxane-based regimens versus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and cyclophosphamide (TC) given for the same duration, finding a benefit overall for incorporation of the anthracycline, particularly in TNBC in subset analysis. However, the absolute benefit in node-negative TNBC appears modest [<a href="#rid37">37</a>]. Further discussion of these data is elsewhere. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Rationale for anthracycline- and taxane-containing regimen'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Non-anthracycline-based regimens are an appropriate alternative for patients with lower-risk TNBC (eg, node-negative, &lt;1 cm, or those with cardiac risk factors) and those who prefer to avoid the risks associated with anthracyclines. TC  (<a class="graphic graphic_table graphicRef56545" href="/d/graphic/56545.html" rel="external">table 6</a>) is an alternative in low-risk disease, and is discussed in more detail elsewhere (in patients with HER2-negative disease, irrespective of hormone receptor status). (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Acceptable alternatives to anthracycline-based treatment'</a>.)</p><p></p><p class="bulletIndent2">For example, in a randomized trial of nearly 650 patients with operable TNBC, those assigned to six cycles of adjuvant <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> (administered on days 1, 8, and 15 every 28 days) had a longer DFS relative to those assigned to an anthracycline and taxane based regimen (five-year DFS 87 versus 80 percent), with similar OS [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for an antimetabolite agent?</strong> – For patients with stage II or III TNBC, neoadjuvant regimens such as AC-T or TC are standard, followed by <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> for those with residual disease, given results of a randomized trial showing an OS benefit with the adjuvant addition of capecitabine when residual disease is present [<a href="#rid39">39</a>]. These results are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Regimen selection and administration'</a>.)</p><p></p><p class="bulletIndent1">However, for patients with stage I disease, adjuvant rather than neoadjuvant treatment is appropriate, using standard regimens such as AC-T or TC. In general, for patients who have not received neoadjuvant chemotherapy, adding antimetabolite agents such as <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> to adjuvant chemotherapy has not improved OS outcomes in TNBC [<a href="#rid40">40,41</a>], and it is not our approach. A Chinese trial demonstrated improvement in DFS, but not OS, with capecitabine following standard adjuvant regimens [<a href="#rid42">42</a>]. Among 434 women with early-stage TNBC who received standard adjuvant treatment (94 percent of whom had not received neoadjuvant therapy), low-dose capecitabine maintenance therapy for one year improved five-year DFS compared with observation only (83 versus 73 percent; hazard ratio [HR] 0.64, 95% CI 0.42-0.95). The five-year OS was similar between the groups (86 versus 81 percent, with and without capecitabine, respectively; HR 0.75, 95% CI 0.47-1.19). The trial had important limitations; notably, there was an imbalance in randomization, with a higher proportion of older women assigned to placebo, which could have favored the capecitabine group. </p><p></p><p class="bulletIndent1">In a separate phase III trial of 876 women with early-stage TNBC who had received standard adjuvant chemotherapy, subsequent treatment with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> versus placebo resulted in numerically, but not statistically, improved five-year DFS and OS (DFS, 80 versus 77 percent, HR 0.79, 95% CI 0.61-1.03; OS, 86.2 versus 85.9 percent, HR 0.92, 95% CI 0.66-1.28) [<a href="#rid40">40</a>]. Similarly, trials looking at adjuvant <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> have proven negative. </p><p></p><p class="bulletIndent1">Given the sum of data, we opt for standard anthracycline- and/or taxane-based chemotherapy regimens as adjuvant therapy in patients with TNBC who have not received neoadjuvant treatment. As discussed, in practice, only lower-risk patients (ie, stage I TNBC) are treated with adjuvant rather than neoadjuvant chemotherapy, as most patients with higher-risk disease receive neoadjuvant therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a role for platinums?</strong> – There is controversy as to whether adding platinum-based chemotherapy should be "standard" in stage II or III TNBC. Trials have shown that adding platinum-based chemotherapy to neoadjuvant regimens can improve the rate of complete pathologic response [<a href="#rid43">43,44</a>]. However, to date, this has not improved OS in women also receiving anthracycline-, alkylator-, and taxane-based treatment. This is discussed further elsewhere. (See  <a class="medical medical_review" href="/d/html/122902.html" rel="external">"Choice of neoadjuvant chemotherapy for HER2-negative breast cancer", section on 'Special considerations for triple-negative disease'</a>.)</p><p></p><p class="headingAnchor" id="H2580780173"><span class="h3">PARP inhibitors for BRCA carriers</span><span class="headingEndMark"> — </span>The poly(ADP-ribose) polymerase (PARP) inhibitor <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a> has regulatory approval by the US Food and Drug Administration for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (<em>BRCA</em>)-mutated, HER2-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'BRCA carriers with high-risk disease'</a>.)</p><p class="headingAnchor" id="H2805800863"><span class="h3">Is there a role for immunotherapy?</span><span class="headingEndMark"> — </span>The incorporation of immunotherapy in neoadjuvant regimens is discussed elsewhere. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> has regulatory approval with chemotherapy for the neoadjuvant treatment of patients with high-risk, early-stage TNBC. (See  <a class="medical medical_review" href="/d/html/122902.html" rel="external">"Choice of neoadjuvant chemotherapy for HER2-negative breast cancer", section on 'Incorporation of immunotherapy with NACT in TNBC'</a>.)</p><p class="headingAnchor" id="H97090260"><span class="h2">Treatment of tumors ≤0.5 cm</span><span class="headingEndMark"> — </span>The prognosis of node-negative, triple-negative tumors ≤0.5 cm is generally favorable, and therefore, the benefits of adjuvant chemotherapy are likely to be very small and must be weighed against the chances of serious side effects of chemotherapy. In general, patients with microinvasive or very small (1 to 5 mm) tumors do not need chemotherapy, although we discuss the issue carefully with such patients, given that a small benefit cannot be ruled out, and, some patients, particularly those with 4 or 5 mm tumors, may reasonably elect to proceed with treatment. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Special populations'</a>.)</p><p>In a retrospective review of almost 4400 patients with small, node-negative TNBCs (6.5 percent with pT1a, 21 percent with pT1b, and 72 percent with pT1c tumors), adjuvant chemotherapy was administered in 53 percent of cases [<a href="#rid45">45</a>]. Patients receiving chemotherapy had more unfavorable baseline characteristics including younger age, larger tumors, and higher tumor grade. In multivariate analysis, adjuvant chemotherapy improved breast cancer-specific survival in the overall group (adjusted HR 0.65, 95% CI 0.48-0.89), but not for the subset of patients with pT1a tumors (adjusted HR 4.28, 95% CI 1.12-16.44). Although limitations of this study include its retrospective nature and that the number of patients with pT1a tumors was small (n = 18), the results suggest that the risks of chemotherapy may outweigh benefits in patients with these small tumors.</p><p>The natural history of small triple-negative tumors was demonstrated in a study of 143 patients with triple-negative tumors up to 1 cm in size and not treated with adjuvant chemotherapy [<a href="#rid46">46</a>]. Patients with triple-negative tumors had a 75 to 89 percent relapse-free survival and over 95 percent distant relapse-free survival at five years. Another study including 363 T1a-bN0 triple-negative tumors from the National Comprehensive Cancer Network (NCCN) database suggested a 90 to 93 percent distant relapse-free survival without chemotherapy [<a href="#rid47">47</a>]. Given the lack of prospective data on women who present with small tumors, the decision to administer adjuvant chemotherapy must be individualized based on patient and provider preferences.</p><p class="headingAnchor" id="H97089718"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The risk of distant recurrence and death peaks approximately three years after diagnosis and declines rapidly thereafter [<a href="#rid31">31</a>]. TNBC is characterized by higher relapse rates during this period of time compared with ER-positive breast cancers, although the latter tend to continue to recur for decades later while TNBCs tend not to do so. Therefore, overall in the long run the absolute risk of recurrence for the two subtypes approach one another. Furthermore, however, TNBC may be more likely to recur in locoregional areas as well as in visceral organs, such as liver, lung, and brain involvement at first recurrence [<a href="#rid48">48-51</a>]. By contrast, TNBC is less likely than ER-positive breast cancer to recur initially in bone [<a href="#rid51">51</a>]. In one study involving 116 patients with triple-negative metastatic breast cancer, brain metastases were the initial site of metastatic disease or occurred during their metastatic course in 14 and 46 percent, respectively [<a href="#rid49">49</a>]. The median survival following a diagnosis of central nervous system metastases is less than six months [<a href="#rid52">52,53</a>]. </p><p>Patients with TNBC have a poorer short-term (first five to seven years) prognosis compared with patients with other breast cancer subtypes [<a href="#rid14">14,26,51,54</a>]. In a 2012 study of 12,902 women who presented to NCCN centers, compared with women with hormone receptor-positive, HER2-negative breast cancer, women with TNBC experienced, at a median follow-up of three years [<a href="#rid51">51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Worse breast cancer-specific survival (HR 2.99, 95% CI 2.59-3.45).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worse OS (HR 2.72, 95% CI 2.39-3.10).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A dramatic increase in death within two years of diagnosis (HR 6.10, 95% CI 4.81-7.74). However, the magnitude of this risk declined substantially over time (HR of death two to six years from diagnosis 2.30, 95% CI 1.39-3.82; HR of death &gt;6 years from diagnosis 0.86, 95% CI 0.30-2.46). Thus, the risk of recurrence and breast cancer mortality for hormone receptor-positive, HER2-negative disease becomes approximately equal to that of triple-negative cancers within the second decade.</p><p></p><p>The risk of late recurrence is low for women with TNBC. In a single-center retrospective series of 783 women with stage I, II, or III TNBC who were alive and without recurrence at five years after treatment for the original diagnosis, the yearly recurrence-free interval at 10 and 15 years was 97 and 95 percent, respectively, and the relapse-free survival rates were 91 and 83 percent, respectively [<a href="#rid55">55</a>]. In a prospective cohort study in which patients with stage I to III breast cancer diagnosed between 1986 and 1992 were matched with patients diagnosed between 2004 and 2008, the hazard rate of relapse for those with triple-negative disease had dropped to essentially zero after year 6 among patients treated in the later cohort [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H97089916"><span class="h2">Post-treatment surveillance</span><span class="headingEndMark"> — </span>There are no specific post-treatment surveillance guidelines for patients with TNBC. Patients with breast cancer should undergo a similar surveillance routine according to American Society of Clinical Oncology guidelines following breast cancer treatment, regardless of breast cancer subtype. This should include history and complete physical exam every three months for the first three years, then every 6 to 12 months for surveillance. A further discussion on post-treatment surveillance is covered separately. (See  <a class="medical medical_review" href="/d/html/15781.html" rel="external">"Approach to the patient following treatment for breast cancer", section on 'Guidelines for post-treatment follow-up'</a>.)</p><p class="headingAnchor" id="H1136598543"><span class="h1">METASTATIC DISEASE</span><span class="headingEndMark"> — </span>Many of the general principles applicable to advanced breast cancer of other phenotypes apply to that of TNBC. Chemotherapy has been the mainstay of systemic treatment for TNBC, as endocrine therapy and HER2-directed therapies are ineffective. However, several trials have suggested a role for targeted therapies in TNBC including inhibitors of poly(ADP-ribose) polymerase (PARP) and immune checkpoints  (<a class="graphic graphic_algorithm graphicRef121095" href="/d/graphic/121095.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p class="headingAnchor" id="H1580707456"><span class="h2">Repeat biopsy</span><span class="headingEndMark"> — </span>In patients with metastatic breast cancer, a confirmatory biopsy of a suspected lesion should be obtained when possible, with the following assessments:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reassessment of ER, PR, and HER2</strong> – This is because there is a possible discordance of these markers between primary and metastatic disease [<a href="#rid57">57-61</a>]. As an example of discordance between primary and metastatic lesions, in a pooled analysis of two prospective studies, the rates of discordance in ER, PR, and HER2 between the primary and recurrent disease were 13, 28, and 5 percent, respectively [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PD-L1 expression</strong> – The companion diagnostic immunohistochemical assay for programmed cell death ligand 1 (PD-L1)-positive immune cells, the 22C3 pharmDX assay, is used to identify patients for <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>. (See <a class="local">'PD-L1 combined positive score of at least 10'</a> below.)</p><p></p><p class="bulletIndent1">Because the US Food and Drug Administration (FDA) has approved each test as a "companion diagnostic" with a specific immune checkpoint inhibitor rather than approval as a class, either of the companion diagnostics is acceptable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TMB, MSI, and dMMR</strong> – Additionally, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair deficiency (dMMR) should be performed if there is sufficient tissue. Further details of testing are found elsewhere. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Assessing mismatch repair'</a> and  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Approach to testing dMMR as a predictive marker'</a>.)</p><p></p><p class="bulletIndent1">However, if needed, these assessments can instead be performed in a subsequent biopsy after progression, given that they will not dictate choice of initial therapy and that these abnormalities are relatively rare in breast cancer. (See <a class="local">'Pembrolizumab for tumors with high TMB or MSI-H/dMMR tumors'</a> below.)</p><p></p><p>In addition to these assays performed on tissue biopsy, all patients with TNBC should undergo genetics evaluation to determine if they are breast cancer susceptibility gene (<em>BRCA) </em>carriers, given the therapeutic implications in advanced disease. (See <a class="local">'No germline BRCA mutation'</a> below and <a class="local">'Germline BRCA mutation'</a> below.)</p><p class="headingAnchor" id="H308523728"><span class="h2">Initial treatment for rapidly progressive visceral disease</span><span class="headingEndMark"> — </span>Combination chemotherapy may be appropriate for those with extensive or rapidly progressive visceral disease, in whom the higher chance of response is thought to outweigh the higher risks of toxicity, due to concerns about impending organ dysfunction. However, both clinicians and patients should know there are no prospective data that show combination chemotherapy improves overall survival (OS) compared with single-agent sequential cytotoxic chemotherapy. Further details are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Combination versus single agent chemotherapy'</a>.)</p><p class="headingAnchor" id="H75333130"><span class="h2">Initial treatment in the absence of rapidly progressive visceral disease</span><span class="headingEndMark"> — </span>As discussed above, patients with metastatic TNBC should have germline testing for <em>BRCA</em>, as well as tumor assessment for PD-L1. (See <a class="local">'Genetics evaluation'</a> above and <a class="local">'Repeat biopsy'</a> above.)</p><p>The initial treatment approach depends on the outcomes of these assessments.</p><p class="headingAnchor" id="H624350455"><span class="h3">No germline BRCA mutation</span></p><p class="headingAnchor" id="H1048655874"><span class="h4">PD-L1 combined positive score &lt;10</span><span class="headingEndMark"> — </span>Our approach to most patients with advanced, sporadic, triple-negative metastatic breast cancer with programmed cell death ligand 1 (PD-L1) combined positive score (CPS) &lt;10 is to use single-agent chemotherapy. However, combination chemotherapy strategies may be appropriate in some such patients with rapidly progressive visceral disease.</p><p>Either platinum- or non-platinum-based regimens are appropriate, with a choice driven by toxicity profiles. In a meta-analysis of 10 randomized trials comparing platinum-containing chemotherapy with regimens not containing platinum in 958 women with metastatic TNBC, the death rate at one year in the platinum group was 46 versus 51 percent in the non-platinum group (hazard ratio [HR] 0.85, 95% CI 0.73-1.00) [<a href="#rid62">62</a>]. However, grade 3 and 4 toxicities were higher among platinum recipients, including nausea/vomiting (relative risk [RR] 4.8) and anemia (RR 3.8).</p><p>Outcomes of platinum and non-platinum regimens in breast cancer susceptibility gene (<em>BRCA</em>)-associated TNBCs are discussed below. (See <a class="local">'Chemotherapy-naϊve patients, or those with progression on PARP inhibitors'</a> below.)</p><p>Further lines of chemotherapy are similar to patients with hormone receptor-positive, HER2-negative disease and are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p class="headingAnchor" id="H947980336"><span class="h4">PD-L1 combined positive score of at least 10</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is approved by the FDA in combination with chemotherapy for patients with metastatic TNBC whose tumors express PD-L1 with a CPS ≥10 (the percentage of total cells [tumor cells, lymphocytes, macrophages] that stain for PD-L1) [<a href="#rid63">63</a>].</p><p>Although <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is used irrespective of treatment line, the supporting data were based on patient experiences receiving first-line treatment for metastatic disease.</p><p>In KEYNOTE 355, 847 patients with locally recurrent, inoperable, or metastatic TNBC, all of whom had a disease-free interval of ≥6 months, were randomly assigned to chemotherapy (<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>/<a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>), with or without <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> [<a href="#rid64">64</a>]. Overall, there was a modest improvement in median progression-free survival (PFS) with the addition of pembrolizumab (7.5 versus 5.6 months; HR 0.82, 95% CI 0.69-0.97). Results were also stratified according to CPS. In patients with CPS ≥10, the addition of pembrolizumab to chemotherapy improved median PFS by approximately four months (9.7 versus 5.6 months; HR 0.65, 95% CI 0.49-0.86). Among patients with CPS ≥1, median PFS was 7.6 versus 5.6 months with and without pembrolizumab, a difference that was not statistically significant (HR 0·74, 95% CI 0.61-0.90). In subsequent reporting, addition of pembrolizumab improved OS among patients with a CPS ≥10 (23.0 versus 16.1 months; HR 0.73, 95% CI 0.55-0.95) [<a href="#rid65">65</a>]. Although there were also improvements in PFS among those with CPS ≥1, there was no statistically significant OS improvement in this subgroup (17.6 versus 16 months).</p><p>Grade 3 to 4 adverse events were comparable between the two groups (approximately 70 percent), although one patient in the <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> arm died from treatment-related toxicity.</p><p><a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">Atezolizumab</a> was previously granted accelerated approval by the FDA in combination with <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> for those with advanced TNBC with PD-L1-stained, tumor-infiltrating immune cells of any intensity covering ≥1 percent of the tumor area, but this approval was withdrawn due to lack of improvement in PFS in IMpassion 131 [<a href="#rid66">66</a>], despite an OS and PFS benefit in IMpassion 130 [<a href="#rid67">67,68</a>].</p><p>In addition to the chemotherapy combination trials noted above, early clinical experience with immunotherapy in the setting of TNBC also includes small studies of the single-agent anti-programmed cell death protein-1 (PD-1) antibody <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> as well as anti-PD-L1 antibodies <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a> and <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> [<a href="#rid69">69-71</a>], with response rates generally &lt;20 percent even in PD-L1-selected tumors. Additional strategies, including combination immunotherapy with other systemic therapy or with radiation, as well as other approaches, are in development. Furthermore, optimization of biomarkers predictive of response to immunotherapy is actively under investigation.</p><p class="headingAnchor" id="H96762488"><span class="h3">Germline BRCA mutation</span></p><p class="headingAnchor" id="H3860141579"><span class="h4">Patients with previous exposure to chemotherapy</span><span class="headingEndMark"> — </span>Inhibitors of PARP may be particularly useful in breast cancer susceptibility gene (<em>BRCA</em>)-mutated breast cancers, of which the majority are triple negative. For most patients with TNBC with germline <em>BRCA</em> mutations who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic disease setting, we suggest an oral inhibitor of PARP rather than chemotherapy, since the data suggest improved efficacy and fewer side effects. However, chemotherapy is appropriate if and when a patient suffers progressive disease on a PARP inhibitor; or for those who are chemotherapy naive, having never received chemotherapy either in the early-stage or metastatic setting; or, as discussed above, for those with rapidly progressive visceral disease. (See <a class="local">'Initial treatment for rapidly progressive visceral disease'</a> above.)</p><p>Additionally, the combination of immunotherapy and chemotherapy is an acceptable alternative to a PARP inhibitor for those with PD-L1-positive disease. (See <a class="local">'Chemotherapy-naϊve patients, or those with progression on PARP inhibitors'</a> below and <a class="local">'PD-L1 combined positive score of at least 10'</a> above.)</p><p>In the OlympiAD trial, among the subset of 121 <em>BRCA</em> mutation carriers with metastatic triple-negative disease, all of whom had received an anthracycline and a taxane in either the adjuvant or metastatic setting, those randomly assigned to <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a> experienced an improved PFS relative to those receiving chemotherapy (HR for progression or death 0.43, 95% CI 0.29-0.63) [<a href="#rid72">72</a>]. The overall study, which also included those with hormone receptor-positive, HER2-negative disease, was also positive, but the improvements noted with olaparib were stronger in the triple-negative population. Similarly, in the TNBC subgroup of the EMBRACA trial, which also enrolled patients with advanced breast cancer and a germline <em>BRCA</em> mutation, <a class="drug drug_general" data-topicid="119387" href="/d/drug information/119387.html" rel="external">talazoparib</a> improved PFS relative to single-agent chemotherapy (HR 0.60, 95% CI 0.41-0.87). Further details of these studies are discussed elsewhere. It should be noted that the comparator single-agent chemotherapy options did not include either taxanes or platinums in these studies, so the trial realistically only compared PARP inhibitors against second-line therapies. It is unknown how PARP inhibitors would compare with first-line drugs. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Special considerations'</a>.)</p><p>There are several other PARP inhibitors in clinical development [<a href="#rid73">73-79</a>]. For example, veliparib (ABT-888) was tested in combination with <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a>, an alkylating agent, among 41 women with advanced TNBC (of whom 8 had a <em>BRCA</em> germline mutation) in a single-arm phase II study [<a href="#rid79">79</a>]. While the overall response and clinical benefit rates were 7 and 17 percent across the entire study population, any activity appeared to be concentrated among the patients with<em> BRCA </em>mutations, in whom the overall response and clinical benefit rates were 37.5 and 62.5 percent, respectively. The results of the ISPY trial that evaluated the combination of veliparib plus <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> when combined with standard chemotherapy as part of a neoadjuvant treatment program in women with TNBC are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/122902.html" rel="external">"Choice of neoadjuvant chemotherapy for HER2-negative breast cancer", section on 'Special considerations for triple-negative disease'</a>.) </p><p>There is mechanistic rationale for use of PARP inhibition as anticancer therapy. PARP is involved in the molecular events leading to cell recovery from DNA damage. When <em>PARP1</em>, the most abundant member of the PARP family, is inhibited, double-strand DNA breaks accumulate and under normal conditions are repaired via the BRCA pathway-dependent homologous recombination mechanism [<a href="#rid80">80</a>]. Investigators hypothesized that inhibition of PARP, in combination with DNA-damaging chemotherapeutics, would render tumors lacking <em>BRCA</em> function exquisitely sensitive, a hypothesis that has borne out in both the preclinical and clinical arenas [<a href="#rid73">73,81-83</a>]. Given the shared clinicopathologic characteristics between <em>BRCA</em>-mutated breast cancer and TNBCs, the efficacy and safety of PARP inhibition is being tested in both settings. However, PARP inhibitors remain investigational for sporadic TNBC.</p><p class="headingAnchor" id="H869644234"><span class="h4">Chemotherapy-naϊve patients, or those with progression on PARP inhibitors</span><span class="headingEndMark"> — </span>Although we typically start with a poly(ADP-ribose) polymerase (PARP) inhibitor for metastatic disease in those with germline <em>BRCA</em> mutations who have had chemotherapy in the (neo)adjuvant setting, chemotherapy is the preferred option for those who have never been exposed to chemotherapy (in the early or metastatic settings); or for those who have experienced progression on a PARP inhibitor; or for those with rapidly progressive visceral disease, as discussed above. (See <a class="local">'Initial treatment for rapidly progressive visceral disease'</a> above.)</p><p>When administering chemotherapy, our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For the subset of patients with <em>BRCA</em>-associated breast cancers that also express PD-L1 with CPS ≥10, we recommend immunotherapy plus chemotherapy as the initial chemotherapy regimen, over other chemotherapy options. (See <a class="local">'PD-L1 combined positive score of at least 10'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, for those with <em>BRCA</em>-associated cancers with PD-L1 CPS&lt;10, chemotherapy rather than chemoimmunotherapy is appropriate. Both platinums and taxanes are considered appropriate options for chemotherapy, with a choice driven by scheduling and toxicity considerations. Guidelines from the American Society of Clinical Oncology have, however, suggested platinum agents over taxanes for <em>BRCA1/2</em> carriers with advanced breast cancers [<a href="#rid84">84</a>], based on a randomized trial of <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> versus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> in first-line therapy of TNBC described below.</p><p></p><p>The TNT randomized trial directly compared <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> in the first-line treatment setting for women with metastatic TNBC. Overall response rates were similar in the overall group, but among the 43 women with a known <em>BRCA1/2</em> mutation, carboplatin resulted in a higher response rate (68 versus 33 percent; absolute difference 35 percent, 95% CI 6.3-63.1 percent) and PFS (6.8 versus 4.4 months; absolute difference 2.6 months, 95% CI 0.11-5.12 months) [<a href="#rid85">85</a>]. However, the trial had a crossover design, and no statistically significant OS difference was seen (12.8 months, 95% CI 10.6-15.3; and 12 months, 95% CI 10.2-13) for those allocated carboplatin or docetaxel, respectively, suggesting that either agent may be administered first, without compromising outcomes.</p><p>Grade ≥3 toxicities among those receiving <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> versus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> included febrile neutropenia in 2 and 20 percent, diarrhea in 3 and 7 percent, and thrombocytopenia in 7 and 0 percent, respectively. Any-grade toxicities for carboplatin versus docetaxel included alopecia in 35 and 89 percent, arthralgias in 4 and 21 percent, diarrhea in 34 and 64 percent, and peripheral neuropathy in 33 and 71 percent, respectively. Fatigue occurred in 95 percent in both arms.</p><p class="headingAnchor" id="H166753628"><span class="h2">Later-line options</span></p><p class="headingAnchor" id="H2455202610"><span class="h3">Fam-trastuzumab deruxtecan in HER2-"low" cancers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">Fam-trastuzumab deruxtecan</a> has regulatory approval in the United States for patients with advanced HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization-negative) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'HER2-low tumors'</a>.)</p><p class="headingAnchor" id="H3864918934"><span class="h3">Sacituzumab govitecan</span><span class="headingEndMark"> — </span>Trop-2 is expressed in the majority of TNBCs. <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> is an antibody-drug conjugate that targets Trop-2 for the selective delivery of SN-38, the active metabolite of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. It is approved by the FDA for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior therapies, at least one of them for metastatic disease [<a href="#rid86">86</a>]. Severe neutropenia and diarrhea may occur with this agent, including cases of neutropenic colitis. Management of enterotoxicity of this agent is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation", section on 'Sacituzumab govitecan'</a>.)</p><p>A randomized trial enrolled patients with metastatic TNBC that was relapsed or refractory to two or more previous standard chemotherapy regimens; prior therapy had to include a taxane (for any indication) [<a href="#rid87">87</a>]. Among 468 patients, those assigned to <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> had improved OS compared with those assigned to clinician's choice of chemotherapy (12.1 versus 6.7 months; HR 0.48, 95% CI 0.38-0.59). They also experienced improvements in PFS (5.6 versus 1.7 months; HR 0.41, 95% CI 0.32-0.52) and objective response rate (35 versus 5 percent). The rates of key grade ≥3 treatment-related adverse events were as follows: neutropenia (51 percent with sacituzumab govitecan and 33 percent with chemotherapy), leukopenia (10 and 5 percent), diarrhea (10 and &lt;1 percent), anemia (8 and 5 percent), and febrile neutropenia (6 and 2 percent).</p><p>Results were consistent with a previous single-arm trial [<a href="#rid88">88</a>].</p><p class="headingAnchor" id="H1177773046"><span class="h3">Pembrolizumab for tumors with high TMB or MSI-H/dMMR tumors</span><span class="headingEndMark"> — </span>The immune checkpoint inhibitor <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> is approved by the FDA for the treatment of unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, as well as tumors with high tumor mutational burden (TMB), that have progressed following prior treatment and that have no satisfactory alternative treatment options. We offer pembrolizumab for immunotherapy-naïve patients with these molecular markers, but only when chemotherapy (and PARP inhibitors, for <em>BRCA</em> carriers) is no longer effective or tolerated. Testing for TMB and dMMR is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Assessing mismatch repair'</a> and  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Approach to testing for high levels of TMB'</a>.)</p><p>We acknowledge, in discussion with patients, that the trials supporting the approval of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> for these indications did not include breast cancer patients, but efficacy was demonstrated in other cancer types, including cervical, endometrial, and ovarian cancer. (See  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Other tumors with MSI-H/dMMR'</a> and  <a class="medical medical_review" href="/d/html/120646.html" rel="external">"Tissue-agnostic cancer therapy: DNA mismatch repair deficiency, tumor mutational burden, and response to immune checkpoint blockade in solid tumors", section on 'Tumors with high mutational burden'</a>.)</p><p class="headingAnchor" id="H4132188764"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119888.html" rel="external">"Society guideline links: Hereditary breast and ovarian cancer"</a> and  <a class="medical medical_society_guidelines" href="/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H98882467"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Triple-negative breast cancer (TNBC) lacks expression of the three most commonly evaluated biomarkers (the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] protein). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TNBCs are typically higher grade, and are more likely to be diagnosed clinically rather than mammographically than ER-positive cancers. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 (<em>BRCA1</em>)-associated breast cancer. (See <a class="local">'Pathologic characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-metastatic disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The principles that apply to the surgical treatment and use of radiation therapy in breast cancer, and the systemic treatment approach in both the neoadjuvant and adjuvant settings, are similar in TNBC and other HER2-negative subtypes. (See <a class="local">'Non-metastatic disease'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with TNBC and either a tumor size &gt;0.5 cm or pathologically involved lymph nodes (regardless of tumor size), we recommend chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>), to be administered in either the adjuvant or neoadjuvant setting. Risk of recurrence increases on a continuum, such that larger tumors are more likely to derive benefit from chemotherapy than smaller ones. In general, patients with tumors 1 to 5 mm do not need chemotherapy, although we discuss the issue carefully with such patients, given that a small benefit cannot be ruled out. (See <a class="local">'Treatment of tumors ≤0.5 cm'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients receiving chemotherapy for non-metastatic TNBC, we suggest an anthracycline- and taxane-based combination, such as dose-dense <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> followed by <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (AC-T  (<a class="graphic graphic_table graphicRef55933" href="/d/graphic/55933.html" rel="external">table 5</a>)) rather than a non-anthracycline-based treatment (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Although no regimen has proved to be superior to AC-T, the non-anthracycline-based regimen <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and cyclophosphamide (TC  (<a class="graphic graphic_table graphicRef56545" href="/d/graphic/56545.html" rel="external">table 6</a>)) is an appropriate alternative for patients who have indications for chemotherapy but have lower-risk disease.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Decisions regarding administration in the neoadjuvant versus adjuvant setting are found elsewhere. (See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer", section on 'Patient selection'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have completed a full course of neoadjuvant treatment, additional chemotherapy in the adjuvant setting for those with residual disease is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer", section on 'Patients who received neoadjuvant treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Despite a higher risk of relapse compared with other breast cancer subtypes, there are no specific post-treatment surveillance guidelines for patients with TNBC; American Society of Clinical Oncology surveillance guidelines apply similarly across subtypes. (See <a class="local">'Post-treatment surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combination chemotherapy for those with rapidly progressive visceral disease</strong> – In the metastatic setting, combination chemotherapy may be appropriate for those with extensive or rapidly progressive visceral disease, in whom the higher chance of response is thought to outweigh the higher risks of toxicity. However, there are no prospective data that show combination chemotherapy improves overall survival (OS) compared with single-agent sequential cytotoxic chemotherapy. (See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer", section on 'Combination versus single agent chemotherapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Single agent chemotherapy for those who are not in visceral crisis</strong> – In the metastatic TNBC setting, for those who are not in visceral crisis, therapy depends on prior treatment history, programmed cell death ligand 1 (PD-L1) expression, and germline <em>BRCA </em>mutation status  (<a class="graphic graphic_algorithm graphicRef121095" href="/d/graphic/121095.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>PD-L1 CPS ≥10</strong> – For TNBC with PD-L1 combined positive score (CPS) ≥10 (in <em>BRCA</em>-wildtype patients, as well as in chemotherapy-naïve germline <em>BRCA </em>carriers), we suggest the combination of <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a> and chemotherapy as initial treatment for metastatic disease, rather than single-agent chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'PD-L1 combined positive score of at least 10'</a> above and <a class="local">'Chemotherapy-naϊve patients, or those with progression on PARP inhibitors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>PD-L1 CPS &lt;10</strong> – For TNBC with PD-L1 CPS &lt;10 (in <em>BRCA</em>-wildtype patients, as well in chemotherapy-naïve <em>BRCA </em>carriers), single-agent chemotherapy remains the preferred initial treatment option and is discussed elsewhere. <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">Pembrolizumab</a> is an appropriate later-line option for those whose tumors have either high tumor mutational burden (TMB) or are microsatellite instability high or mismatch repair deficient (dMMR). (See <a class="local">'PD-L1 combined positive score &lt;10'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong><em>BRCA</em></strong><strong> carriers with previous exposure to chemotherapy</strong> – For <em>BRCA </em>carriers with previous exposure to chemotherapy in the neoadjuvant/adjuvant setting, we suggest an inhibitor of poly(ADP-ribose) polymerase (PARP) as initial treatment for metastatic disease (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>), although chemotherapy is also acceptable, particularly in those with PD-L1-positive disease, in whom chemotherapy plus an immune checkpoint inhibitor is an appropriate alternative. (See <a class="local">'Germline BRCA mutation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Later line option</strong> – <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">Sacituzumab govitecan</a> is an antibody-drug conjugate that targets Trop-2 for the selective delivery of SN-38, the active metabolite of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, and is an option for patients with metastatic TNBC who have received at least two prior therapies, at least one of which was for metastatic disease. (See <a class="local">'Sacituzumab govitecan'</a> above and <a class="local">'Pembrolizumab for tumors with high TMB or MSI-H/dMMR tumors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134:e48.</a></li><li><a class="nounderline abstract_t">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28:2784.</a></li><li><a class="nounderline abstract_t">Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31:3997.</a></li><li class="breakAll">Swain S. Triple-Negative Breast Cancer: Metastatic Risk and Role of Platinum Agents 2008 ASCO Clinical Science Symposium, 2008. June 3, 2008.</li><li><a class="nounderline abstract_t">Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20:1071.</a></li><li><a class="nounderline abstract_t">Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17:1082.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk assessment: Breast and Ovarian. Version 4.2013. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf (Accessed on November 26, 2013).</li><li><a class="nounderline abstract_t">Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123.</a></li><li><a class="nounderline abstract_t">Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15:593.</a></li><li><a class="nounderline abstract_t">Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295:2492.</a></li><li><a class="nounderline abstract_t">Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011; 103:470.</a></li><li><a class="nounderline abstract_t">Palmer JR, Viscidi E, Troester MA, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137:307.</a></li><li><a class="nounderline abstract_t">Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429.</a></li><li><a class="nounderline abstract_t">Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14:1108.</a></li><li><a class="nounderline abstract_t">Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264.</a></li><li><a class="nounderline abstract_t">Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21:1688.</a></li><li><a class="nounderline abstract_t">Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236.</a></li><li><a class="nounderline abstract_t">Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395.</a></li><li><a class="nounderline abstract_t">Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26S: ASCO #1009.</a></li><li><a class="nounderline abstract_t">Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82:1525.</a></li><li><a class="nounderline abstract_t">Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367.</a></li><li><a class="nounderline abstract_t">Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750.</a></li><li><a class="nounderline abstract_t">Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157.</a></li><li><a class="nounderline abstract_t">Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.</a></li><li><a class="nounderline abstract_t">Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869.</a></li><li><a class="nounderline abstract_t">Troester MA, Herschkowitz JI, Oh DS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006; 6:276.</a></li><li><a class="nounderline abstract_t">Cheang MC, Martin M, Nielsen TO, et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. J Clin Oncol 2012; 30S: ASCO #1008.</a></li><li><a class="nounderline abstract_t">Iwamoto T, Booser D, Valero V, et al. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 2012; 30:729.</a></li><li><a class="nounderline abstract_t">Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol 2017; 3:549.</a></li><li><a class="nounderline abstract_t">Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275.</a></li><li><a class="nounderline abstract_t">von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796.</a></li><li><a class="nounderline abstract_t">Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.</a></li><li><a class="nounderline abstract_t">Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496.</a></li><li><a class="nounderline abstract_t">Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27:1168.</a></li><li><a class="nounderline abstract_t">Martín M, Rodríguez-Lescure A, Ruiz A, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010; 123:149.</a></li><li><a class="nounderline abstract_t">Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 2017; 35:2647.</a></li><li><a class="nounderline abstract_t">Yu KD, Ye FG, He M, et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2020; 6:1390.</a></li><li><a class="nounderline abstract_t">Masuda N, Lee SJ, Ohtani S, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017; 376:2147.</a></li><li><a class="nounderline abstract_t">Lluch A, Barrios CH, Torrecillas L, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol 2020; 38:203.</a></li><li><a class="nounderline abstract_t">Li J, Yu K, Pang D, et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol 2020; 38:1774.</a></li><li><a class="nounderline abstract_t">Wang X, Wang SS, Huang H, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA 2021; 325:50.</a></li><li><a class="nounderline abstract_t">von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15:747.</a></li><li><a class="nounderline abstract_t">Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33:13.</a></li><li><a class="nounderline abstract_t">Steenbruggen TG, van Werkhoven E, van Ramshorst MS, et al. Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer 2020; 135:66.</a></li><li><a class="nounderline abstract_t">Theriault RL, Litton JK, Mittendorf EA, et al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 2011; 11:325.</a></li><li><a class="nounderline abstract_t">Vaz-Luis I, Ottesen RA, Hughes ME, et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol 2014; 32:2142.</a></li><li><a class="nounderline abstract_t">Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68:3108.</a></li><li><a class="nounderline abstract_t">Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638.</a></li><li><a class="nounderline abstract_t">Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30:1097.</a></li><li><a class="nounderline abstract_t">Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012; 118:5463.</a></li><li><a class="nounderline abstract_t">Niwińska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010; 116:4238.</a></li><li><a class="nounderline abstract_t">Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2011; 117:1602.</a></li><li><a class="nounderline abstract_t">Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418.</a></li><li><a class="nounderline abstract_t">Reddy SM, Barcenas CH, Sinha AK, et al. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 2018; 118:17.</a></li><li><a class="nounderline abstract_t">Cossetti RJ, Tyldesley SK, Speers CH, et al. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J Clin Oncol 2015; 33:65.</a></li><li><a class="nounderline abstract_t">Hull DF 3rd, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43:413.</a></li><li><a class="nounderline abstract_t">Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol 2010; 28S: ASCO #1007.</a></li><li><a class="nounderline abstract_t">Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20:1499.</a></li><li><a class="nounderline abstract_t">Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009; 10:933.</a></li><li><a class="nounderline abstract_t">Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011; 13:17.</a></li><li><a class="nounderline abstract_t">Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. Cochrane Database Syst Rev 2020; 10:CD013750.</a></li><li class="breakAll">Pembrolizumab injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf (Accessed on November 13, 2020).</li><li><a class="nounderline abstract_t">Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020; 396:1817.</a></li><li><a class="nounderline abstract_t">Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387:217.</a></li><li><a class="nounderline abstract_t">Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021; 32:994.</a></li><li><a class="nounderline abstract_t">Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379:2108.</a></li><li><a class="nounderline abstract_t">Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol 2021; 32:983.</a></li><li><a class="nounderline abstract_t">Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2019; 30:397.</a></li><li><a class="nounderline abstract_t">Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2018; 167:671.</a></li><li><a class="nounderline abstract_t">Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res 2018; 24:511.</a></li><li><a class="nounderline abstract_t">Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377:523.</a></li><li><a class="nounderline abstract_t">Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27S: ASCO #CRA501.</a></li><li><a class="nounderline abstract_t">Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123.</a></li><li><a class="nounderline abstract_t">Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235.</a></li><li><a class="nounderline abstract_t">Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010; 28S: ASCO #3002.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205.</a></li><li><a class="nounderline abstract_t">Dent RA, Lindeman GJ, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28S: ASCO #1018.</a></li><li><a class="nounderline abstract_t">Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28S: ASCO #1019.</a></li><li><a class="nounderline abstract_t">Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52:25.</a></li><li><a class="nounderline abstract_t">Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913.</a></li><li><a class="nounderline abstract_t">Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009; 27S: ASCO #3.</a></li><li><a class="nounderline abstract_t">Tung NM, Boughey JC, Pierce LJ, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol 2020; 38:2080.</a></li><li><a class="nounderline abstract_t">Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018; 24:628.</a></li><li class="breakAll">Sacituzumab govitecan-hziy injection. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf (Accessed on May 11, 2021).</li><li><a class="nounderline abstract_t">Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med 2021; 384:1529.</a></li><li><a class="nounderline abstract_t">Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med 2019; 380:741.</a></li></ol></div><div id="topicVersionRevision">Topic 14227 Version 85.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20586616" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404251" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101045" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24101045" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19343511" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The epidemiology of triple-negative breast cancer, including race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233401" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21233401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578664" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of basal-like breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19764994" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16757721" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21346227" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224496" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23179600" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17671126" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Triple-negative breast cancer: clinical features and patterns of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894660" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16341146" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25208879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18398844" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : How basal are triple-negative breast cancers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22495314" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The clonal and mutational evolution spectrum of primary triple-negative breast cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12429812" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328174" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21633166" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17683518" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553815" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17150101" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Gene expression patterns associated with p53 status in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291085" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918753" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250347" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508812" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609087" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17928597" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HER2 and response to paclitaxel in node-positive breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19204205" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20037779" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28398846" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32789480" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28564564" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31804894" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32275467" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33300950" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24794243" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092775" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32554215" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adjuvant chemotherapy in small node-negative triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21764391" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888816" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18451135" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Subtypes of breast cancer show preferential site of relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18833576" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16931954" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22544643" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20549816" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21472708" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829800" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Repeated observation of breast tumor subtypes in independent gene expression data sets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29235566" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422485" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6847780" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Multiple estrogen receptor assays in human breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19299408" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796747" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21053108" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084020" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Platinum-containing regimens for triple-negative metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084020" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Platinum-containing regimens for triple-negative metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33278935" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35857659" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34219000" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345906" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34272041" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30475950" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29063313" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801472" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Breast Cancer Immunotherapy: Facts and Hopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28578601" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19553641" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609467" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208101" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Iniparib plus chemotherapy in metastatic triple-negative breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911331" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Chemopotentiation by PARP inhibitors in cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829966" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15829967" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243226" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29713086" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29713086" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33882206" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786188" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
